此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Microbiome and Enteric Signatures in Sepsis-associated Hepatorenal Injury (MESH)

2026年7月28日 更新者：First Affiliated Hospital of Zhejiang University

The Impact of Gut Microbiota on Sepsis-Associated Acute Hepatorenal Injury: A Prospective, Multicenter, Observational Study

Sepsis is a major cause of morbidity and mortality in intensive care units. Sepsis-associated liver injury (SALI) and sepsis-associated acute kidney injury (S-AKI) are common complications associated with adverse clinical outcomes. Altered gut microbial diversity, microbial metabolites, intestinal barrier dysfunction, and systemic inflammation may contribute to hepato-renal injury during sepsis; however, prospective longitudinal evidence in patients with SALI and S-AKI remains limited.

This prospective, multicenter, longitudinal observational cohort study will enroll adult patients with sepsis across five medical centers and healthy adult volunteers as a baseline reference cohort. For patients with sepsis, stool and blood samples will be collected on Day 0, Days 3-5, Days 7-10, and Days 14-20 after sepsis diagnosis. Healthy volunteers will provide a single baseline stool and blood sample at enrollment. Fecal microbial alpha diversity and community structure will be assessed by metagenomic sequencing and bioinformatic analysis. Plasma metabolites, including total short-chain fatty acids, indoxyl sulfate, and additional targeted plasma metabolites, will be measured by ultra-high-performance liquid chromatography-tandem mass spectrometry. Intestinal barrier and clinical biomarkers will also be assessed.

The primary objectives are to evaluate the associations between baseline fecal microbial alpha diversity, measured by the Shannon diversity index, and SALI and S-AKI occurring within 7 days after sepsis diagnosis. Secondary objectives include evaluating the associations of baseline fecal microbial beta diversity with SALI and with S-AKI occurring within 7 days after sepsis diagnosis, characterizing longitudinal changes in fecal microbial alpha diversity, measuring plasma metabolite and intestinal biomarker concentrations at prespecified time points, and assessing 28-day all-cause mortality. Exploratory multi-omics analyses will evaluate Proteobacteria and additional microbial taxa, microbial functional genes, metabolites, and host biomarkers. This study aims to identify candidate biomarkers and biological pathways relevant to hepato-renal injury in sepsis.

研究概览

地位

招聘中

条件

研究类型

观察性的

注册 (估计的)

200

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

学习地点

  • 中国
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310000
        • 招聘中
        • First Affiliated Hospital of Zhejiang University School of Medicine
        • 接触：

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

取样方法

非概率样本

研究人群

The study population comprises two distinct groups recruited from multiple clinical centers. The primary clinical cohort consists of critically ill adult patients (aged ≥ 18 years) admitted to the Intensive Care Unit (ICU) who are diagnosed with sepsis according to the Sepsis-3 criteria and enrolled within 24 hours after sepsis diagnosis. This cohort will be monitored to observe longitudinal changes in the gut microbiome and the occurrence of sepsis-associated liver injury (SALI) and sepsis-associated acute kidney injury (S-AKI) from Day 0 through Day 7 after sepsis diagnosis. The secondary control cohort consists of healthy adult volunteers recruited from the community. These volunteers have no history of chronic underlying diseases or recent antibiotic/probiotic use, and they serve to establish baseline healthy profiles for the gut microbiome and circulating metabolites.

描述

Inclusion Criteria:

-

For Sepsis Patients:

  1. Age ≥ 18 years；
  2. Admitted to the Intensive Care Unit (ICU) and meets the Sepsis-3 diagnostic criteria (an acute change in total Sequential Organ Failure Assessment [SOFA] score ≥ 2 points consequent to the infection).
  3. Diagnosed with sepsis within 24 hours prior to enrollment.
  4. Informed consent signed by the patient or a legally authorized representative.

For Healthy Volunteers:

  1. Age ≥ 18 years.
  2. No chronic underlying diseases (including liver, kidney, gastrointestinal, or immune-related disorders).
  3. No use of antibiotics or probiotics, and no history of acute infection within 1 month prior to enrollment (to ensure baseline consistency).
  4. Informed consent signed by the volunteer.

Exclusion Criteria:

  1. History of chronic liver disease (e.g., cirrhosis, chronic hepatitis B/C, autoimmune hepatitis, hepatic carcinoma).
  2. History of chronic kidney disease (e.g., glomerulonephritis, IgA nephropathy).
  3. History of inflammatory bowel disease (including ulcerative colitis and Crohn's disease) or previous major intestinal resection.
  4. Patients with malignant tumors currently receiving chemotherapy or radiotherapy.
  5. Expected survival time of less than 72 hours.
  6. Pregnant or lactating women.
  7. Concurrent participation in other interventional clinical trials.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

队列和干预

团体/队列
Sepsis Patients
Adult patients (age ≥ 18 years) admitted to the ICU who meet the Sepsis-3.0 diagnostic criteria within 24 hours after sepsis diagnosis. This cohort will be longitudinally monitored with biospecimen collection at four time points (Day 0, 3-5, 7-10, and 14-20). Based on clinical progression from Day 0 through Day 7 after sepsis diagnosis, participants will be further categorized into subgroups: Sepsis Control (neither SALI nor S-AKI from Day 0 through Day 7 after sepsis diagnosis), Sepsis-Associated Liver Injury (SALI), and Sepsis-Associated Acute Kidney Injury (S-AKI) for comparative analysis. Participants meeting criteria for both SALI and S-AKI will be included in both outcome-specific analyses.
Healthy Volunteers
Healthy adult volunteers (age ≥ 18 years) without chronic underlying diseases (e.g., liver, kidney, or gastrointestinal disorders) and no history of antibiotic or probiotic use within the past month. This cohort serves as a baseline control to establish the normal range for gut microbiota and metabolic profiles; biospecimens will be collected only once at the time of enrollment.

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Association of Baseline Gut Microbial Alpha Diversity With Sepsis-Associated Acute Kidney Injury
大体时间：Baseline stool sample collected on Day 0 or within 24 hours after sepsis diagnosis; S-AKI assessed from Day 0 through Day 7 after sepsis diagnosis.
Sepsis-associated acute kidney injury (S-AKI) occurring from Day 0 through Day 7 after sepsis diagnosis, assessed according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria using serum creatinine and urine output obtained from routine clinical laboratory testing and medical records. Baseline fecal microbial alpha diversity will be measured using the Shannon diversity index (unitless), calculated from metagenomic sequencing and bioinformatic analysis of a stool sample collected on Day 0 or, if unavailable, within 24 hours after sepsis diagnosis. The association between the Shannon diversity index and S-AKI will be estimated using multivariable logistic regression and reported as an adjusted odds ratio per 1-unit increase in the Shannon diversity index.
Baseline stool sample collected on Day 0 or within 24 hours after sepsis diagnosis; S-AKI assessed from Day 0 through Day 7 after sepsis diagnosis.
Association of Baseline Gut Microbial Alpha Diversity With Sepsis-Associated Liver Injury
大体时间：Baseline stool sample collected on Day 0 or within 24 hours after sepsis diagnosis; SALI assessed from Day 0 through Day 7 after sepsis diagnosis.
Sepsis-associated liver injury (SALI) occurring from Day 0 through Day 7 after sepsis diagnosis, assessed using routine clinical laboratory measurements. SALI is defined by at least one of the following: total bilirubin (TBIL) >2 mg/dL and international normalized ratio (INR) >1.5; alanine aminotransferase (ALT) ≥5 times the upper limit of normal (ULN); alkaline phosphatase (ALP) ≥2 times ULN; or ALT ≥3 times ULN with TBIL ≥2 times ULN. Baseline fecal microbial alpha diversity will be measured using the Shannon diversity index (unitless), calculated from metagenomic sequencing and bioinformatic analysis of a stool sample collected on Day 0 or, if unavailable, within 24 hours after sepsis diagnosis. The association between the Shannon diversity index and SALI will be estimated using multivariable logistic regression and reported as an adjusted odds ratio per 1-unit increase in the Shannon diversity index.
Baseline stool sample collected on Day 0 or within 24 hours after sepsis diagnosis; SALI assessed from Day 0 through Day 7 after sepsis diagnosis.

次要结果测量

结果测量
措施说明
大体时间
Association of Baseline Fecal Microbial Beta Diversity With Sepsis-Associated Liver Injury
大体时间：Baseline stool sample collected on Day 0 or within 24 hours after sepsis diagnosis; SALI assessed from Day 0 through Day 7 after sepsis diagnosis.
Sepsis-associated liver injury (SALI) occurring from Day 0 through Day 7 after sepsis diagnosis, assessed using routine clinical laboratory measurements according to the prespecified SALI criteria. Baseline fecal microbial beta diversity will be assessed using Bray-Curtis dissimilarity (unitless), calculated from metagenomic sequencing data and bioinformatic taxonomic profiling of a stool sample collected on Day 0 or, if unavailable, within 24 hours after sepsis diagnosis. Differences in baseline fecal microbial community composition between the SALI group and the sepsis control group will be evaluated using permutational multivariate analysis of variance (PERMANOVA) and reported as the PERMANOVA R-squared value (R²; unitless).
Baseline stool sample collected on Day 0 or within 24 hours after sepsis diagnosis; SALI assessed from Day 0 through Day 7 after sepsis diagnosis.
Association of Baseline Fecal Microbial Beta Diversity With Sepsis-Associated Acute Kidney Injury
大体时间：Baseline stool sample collected on Day 0 or within 24 hours after sepsis diagnosis; S-AKI assessed from Day 0 through Day 7 after sepsis diagnosis.
Sepsis-associated acute kidney injury (S-AKI) occurring from Day 0 through Day 7 after sepsis diagnosis, assessed according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria using serum creatinine and urine output obtained from routine clinical laboratory testing and medical records. Baseline fecal microbial beta diversity will be assessed using Bray-Curtis dissimilarity (unitless), calculated from metagenomic sequencing data and bioinformatic taxonomic profiling of a stool sample collected on Day 0 or, if unavailable, within 24 hours after sepsis diagnosis. Differences in baseline fecal microbial community composition between the S-AKI group and the sepsis control group will be evaluated using permutational multivariate analysis of variance (PERMANOVA) and reported as the PERMANOVA R-squared value (R²; unitless).
Baseline stool sample collected on Day 0 or within 24 hours after sepsis diagnosis; S-AKI assessed from Day 0 through Day 7 after sepsis diagnosis.
Total Plasma Short-Chain Fatty Acid Concentration
大体时间：Days 0, 3-5, 7-10, and 14-20 after sepsis diagnosis.
Total plasma short-chain fatty acid concentration will be reported as a single aggregate value at each prespecified time point. It will be calculated as the sum of plasma acetate, propionate, and butyrate concentrations, all measured in μmol/L by ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS).
Days 0, 3-5, 7-10, and 14-20 after sepsis diagnosis.
Plasma Indoxyl Sulfate Concentration
大体时间：Days 0, 3-5, 7-10, and 14-20 after sepsis diagnosis.
Plasma indoxyl sulfate concentration will be measured by UPLC-MS/MS and reported in μmol/L at each prespecified time point.
Days 0, 3-5, 7-10, and 14-20 after sepsis diagnosis.
Fecal Calprotectin Concentration
大体时间：Days 0, 3-5, 7-10, and 14-20 after sepsis diagnosis.
Fecal calprotectin concentration will be measured using a validated fecal calprotectin immunoassay and reported in μg/g of stool at each prespecified time point.
Days 0, 3-5, 7-10, and 14-20 after sepsis diagnosis.
28-Day All-Cause Mortality
大体时间：Day 28 after sepsis diagnosis.
All-cause mortality within 28 days after sepsis diagnosis, reported as the percentage (%) of enrolled participants who die. Vital status will be ascertained from medical records and follow-up contact.
Day 28 after sepsis diagnosis.
Longitudinal Change in Fecal Microbial Alpha Diversity Among Patients With Sepsis
大体时间：Day 0 through Days 14-20 after sepsis diagnosis, with assessments on Day 0, Days 3-5, Days 7-10, and Days 14-20.
Fecal microbial alpha diversity will be measured using the Shannon diversity index (unitless), calculated from metagenomic sequencing data and bioinformatic analysis of stool samples collected on Day 0, Days 3-5, Days 7-10, and Days 14-20 after sepsis diagnosis. Longitudinal changes in the Shannon diversity index among patients with sepsis will be evaluated using a linear mixed-effects model accounting for repeated measurements within participants. The outcome will be reported as the model-estimated mean Shannon diversity index (unitless) at each prespecified time point. Healthy volunteers will not be included in this longitudinal analysis because stool samples are collected only once at enrollment.
Day 0 through Days 14-20 after sepsis diagnosis, with assessments on Day 0, Days 3-5, Days 7-10, and Days 14-20.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

First Affiliated Hospital of Zhejiang University

合作者

Ningbo Medical Center Lihuili Hospital
The Second Affiliated Hospital of Jiaxing University
Lin'an Traditional Chinese Medicine Hospital
Taizhou Enze Medical Center Group

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年2月15日

初级完成 (估计的)

2028年2月14日

研究完成 (估计的)

2028年2月14日

研究注册日期

首次提交

2026年7月15日

首先提交符合 QC 标准的

2026年7月28日

首次发布 (实际的)

2026年7月29日

研究记录更新

最后更新发布 (实际的)

2026年7月29日

上次提交的符合 QC 标准的更新

2026年7月28日

最后验证

2026年2月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • IIT20260155B-R2

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅